Table 1.
Patient Characteristics
| Total Patients (n = 237) | Value |
|---|---|
| Age, n (%) | |
| 75–79 | 114 (48) |
| 80–84 | 84 (35) |
| ≥85 | 39 (17) |
| Sex, n (%) | |
| Male | 104 (44) |
| Female | 133 (56) |
| ECOG Performance Status, n (%) | |
| 0–1 | 144 (61) |
| 2 | 71 (30) |
| ≥3 | 22 (9) |
| Primary Tumor Location, n (%) | |
| Head | 122 (52) |
| Body/tail | 112 (47) |
| Unknown | 3 (1) |
| Metastatic Sites, n (%)a | |
| Liver | 168 (71) |
| Lung | 64 (27) |
| Peritoneum | 72 (30) |
| Node | 119 (50) |
| Bone | 9 (4) |
| Other | 10 (4) |
| Median Comorbidity/Polypharmacy (Range) | |
| Number of comorbid conditions | 1 (0–4) |
| Charlson Comorbidity index | 5 (4–14) |
| Number of medications | 7 (0–18) |
| Serum Albumin (n = 234), n (%)b | |
| ≥4.0 g/dL | 67 (29) |
| 3.5 to <4.0 g/dL | 72 (31) |
| <3.5 g/dL | 95 (40) |
| Serum CA 19-9 (n = 217), n (%)c | |
| Normal (0–40 U/mL) | 37 (17) |
| >ULN to ≤59 times ULN | 110 (51) |
| >59 times ULN | 70 (32) |
Abbreviations: CA = carcinoma antigen; ECOG = Eastern Cooperative Oncology Group; ULN = upper limit of normal.
a
Multiple patients had multiple sites of metastatic disease and therefore the total is > 237 and the total percentage for the category metastatic sites is > 100%.
b
Only 234 patients had data on serum albumin level at the time of diagnosis.
c
Only 217 patients had data on CA 19-9 level at the time of diagnosis.